ADDRESS TO:

and the same
~ <u></u>
-
<u>و</u>
-

HODI

u

0

ħJ

đ

UTILITY PATENT APPLICATION TOANGMITTAL

persons are required to		lection of information unless it displays a valid OMB control number	ç
Attorney Docket No.		8819	ā
First Inventor		Patricia Lee Christon, et al.	V.
Assignee	The	Procter & Gamble Company	-5
Title	Abs	orbent Article	65
		ET194808919US	-

110 010 010 1111	Assignee	1	
(Only for new nonprovisional applications		Abso	orbent Arti
under 37 CFR 1.53(b))	Title		
	Express Mall I	abel No.	1

er the Paperwork Reduction Act of 1995, no

See MPEP Chapter 600 concerning utility patent application contents

APPLICATION ELEMENTS

1. [X] Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)

- 2. [X] Specification Total Pages [] (preferred arrangement set forth below)
 - Descriptive Title of the invention
 - Cross References to Related Applications Statement Regarding Fed sponsored R&D
 - Reference to sequence listing, a table, or a computer
 - program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)

[X] Customer Number

- Abstract of the Disclosure
- 3. [X] Drawing(s) (35 USC §113) Total Sheets [3] 4. Oath or Declaration Total pages []
- [] Newly executed (original or copy)
 - Copy from a prior application (37 CFR §1.63(d)) (for continuation/divisional with Box 17 complete
 - [] DELETION OF INVENTORS Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§1.63(d)(2) and 1,33(b).
- 5. [] Application Data Sheet. See 37 CFR §1.76

Assistant Commissioner for Patents Washington, D.C. 20231 6. II CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

Box Patent Application

- 7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. [] Computer Readable Form (CRF) b. Specification Sequence Listing on:
 - i. II CD-ROM or CD-R (2 copies); or ii. Il Paper
 - c. IT Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- 8. IT Assignment Papers (cover sheet & document(s)) 9. II 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignee)
- English Translation Document (If epplicable)
- 11. Il Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations
- 12. II Preliminary Amendment
- 13. [X] Return Receipt Postcard (MPEP 503)
- (Should be specifically itemized) 14. [] Certified Copy of Priority Document(s)
- (if foreign priority is claimed) II Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.

	16.	0	Other	: .	
 If a CONTINUING APPLICATION, check appropriate box and s 	upply	the	e requisi	te i	nformation below and in a prelimina

t, or in an Application Data Sheet under 37 CFR §1.76: □ Continuation
 □ Divisional II Continuation-in-part (CIP) Prior application information: Examiner:

of prior application No._/

Group/Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS (Insert Customer No. here) 27752

	Name (Print/Type)	Theodore P. Cumming	Regis	tration No. (Attorney/Agent)	40,973
į	Signature			Date	December 19, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the emount of time you are required to complete this form should be sent to the Chief Information Officer, Patient and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO See Pearly Application, Assistant Commissions for Patients, Washington, D.C. 20231. (Revised for P&G use 12/7/01)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number					
FEE TRANSMITTAL		Complete if Known			
for FY 2002	Application Number	To Be Assigned			
Patent fees are subject to annual revision.	Confirmation Number	To Be Assigned			
	Filing Date	December 19, 2001			
	First Named Inventor	Patricia Lee Christon, et al.			
	Examiner Name	To Be Assigned			
	Group/Art Unit	To Be Assigned			
TOTAL AMOUNT OF PAYMENT (\$)740.00	Attorney Docket No.	8819			

The Commissioner is hereby authorized to charge indicated fees and credit any over payments to: Deposit Account Number 16-2480 Deposit Account Name The Proeter & Gamble Company Charge Any Additional Fee Roquired Under status. 37 C.F.R. §§1.16 and 1.17	Code (5) 105 130 127 50 139 130 147 2,520	IONAL FEES Fee Description Surcharge-late filing fee or oath Surcharge-late provisional filing fee or cover sheet	: Paud
Deposit Account Number 16-2480 Deposit Account Name The Procter & Gamble Company	105 130 127 50 139 130 147 2,520	Surcharge-late filing fee or oath	
Deposit Account Name The Procter & Gamble Company	105 130 127 50 139 130 147 2,520	Surcharge-late filing fee or oath	
	139 130 147 2,520	Surcharge-late provisional filing fee or cover sheet	D
	147 2,520		
Charge Any Additional Fee Required Under status. 37 C.F.R. §§1.16 and 1.17		Non-English specification	ñ
		For filing a request for ex parte reexamination	Ö
	112 920*	Requesting publication of SIR prior to	
		Examiner's action	n
FEE CALCULATION	113 1 840*	Requesting publication of SIR after	u
FEE CALCULATION	115 1,040	Examiner's action	D
1. BASIC FILING FEE - Large Entity	115 110	Extension for reply within 1st month	
1. BASIC FILING FEE - Large Entry	116 400	Extension for reply within 1 month	Ω
		• • •	1)
Code (\$) <u>Fee Description</u> <u>Fee Paid</u>	117 920	Extension for reply within 3rd month	n
101 740 Utility filing fee [740]	118 1,440	Extension for reply within 4th month	Ω
106 330 Design filing fee []	128 1,960	Extension for reply within 5th month	0
108 740 Reissue filing fee []	119 320	Notice of Appeal	ū
114 160 Provisional filing fee []	120 320	Filing a brief in support of an appeal	Ð
	121 280	Request for oral hearing	D
SUBTOTAL (1) (\$)[740]	138 1,510	Petition to institute a public use proceeding	D
	140 110	Petition to revive - unavoidable	0
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE - Large Entity	141 1,280	Petition to revive - unintentional	0
	142 1,280	Utility issue fee (or reissue)	0
Extra Fee from Fee	143 460	Design issue fee	D
Claims Below Pard	122 130	Petitions to the Commissioner	0
Total Claims [18] - 20** = [0] x [] =[0]	123 50	Petitions related to provisional applications	Ð
	ł	(37 C.F.R. 1.17(q))	
Independent Claims [2] - 3** = [0] x [84] = [0]	126 180	Submission of Information Disclosure Statement	0
Multiple Dependent [] =[]	146 740	Filing a submission after final rejection	
** or number previously paid, if greater; For Reissues, see below	i	(37 CFR § 1.129(a))	O.
	149 740	For each additional invention to be	
Code (\$) Fee Description	l	examined (37 CFR §1.129(b)	D
103 18 Claims in excess of 20	179 740	Request for Continued Examination (RCE)	D
102 84 Independent claims in excess of 3	169 900	Request for expedited examination	D.
	J	of a design application	
104 280 Multiple dependent claim, if not paid	091 1280	Acceptance of unintentionally delayed claim for	0
109 84 **Reissue independent claims over original patent	1	priority under 35 U.S.C. 119, 120, 121, or 365 (a) or	(c)
110 18 **Reissue claims in excess of 20 & over original patent	1		
		pecify)	D
		pecify)	D
	1		
SUBTOTAL (2) (S)[0]	* Reduced	by Basic Filing Fee Paid SUBTOTAL(3)	(S) []

SUBMITTED BY				Complete (if applicable)		
Name (Print/Type)	Theodore P.	Cummings	Registration No. (Attorney/Agent)	40,973	Telephone	(513) 634-1906
Signature				Provide credit and information and	Date	12/19/01

Barden Hour Statement This form is extended to also to Davin Confede to a reliable to the statement of the book. Provide credit one inhumbers and an absonance of PLOVA and a statement of the policy (Revised for P&G use 12/7/01)